/
HLN
$9.33+$0.00 (+0.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$40.7B
4,407M shares
52-week range
$8.65 – $11.28
26% from low
Exchange
NYSE
ADRC
Borrow rate
0.55%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$1.92
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $8.48B | $9.89B | $9.54B | $10.86B | $11.30B | $11.23B | $11.03B |
| Cost of revenue | $3.68B | $3.98B | $3.60B | $4.28B | $4.34B | $4.29B | $3.83B |
| Gross profit | $4.80B | $5.91B | $5.95B | $6.58B | $6.96B | $6.95B | $6.99B |
| Gross margin | 56.6% | 59.7% | 62.3% | 60.6% | 61.6% | 61.9% | 63.3% |
| R&D | $292.0M | $304.0M | $257.0M | $300.0M | $311.0M | $298.0M | $308.1M |
| Operating income | $897.0M | $1.60B | $1.64B | $1.82B | $2.00B | $2.21B | $2.41B |
| EBITDA | $1.17B | $1.91B | $2.21B | $2.18B | $2.35B | $2.51B | $2.88B |
| Net income | $655.0M | $1.15B | $1.39B | $1.06B | $1.05B | $1.44B | $1.63B |
| Net margin | 7.7% | 11.6% | 14.6% | 9.8% | 9.3% | 12.8% | 14.8% |
| EPS (diluted) | 0.14 | 0.24 | 0.30 | 0.24 | 0.24 | 0.32 | 0.36 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11.5B | $0.42 | $0.41–$0.42 | 5 |
| 2027 | $12.0B | $0.46 | $0.45–$0.46 | 5 |
| 2028 | $12.5B | $0.50 | $0.48–$0.54 | 7 |
| 2029 | $13.0B | $0.54 | $0.54–$0.55 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$20.70
Price
$9.33
Implied upside
+122%
Peer comparison
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
www.haleon.com- Employees
- 24,524
- IPO / List date
- Jul 18, 2022
Held by traders on TradeandTell
No one on the platform currently holds HLN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 1,434,399 | $12.9M |
| Bridgewater Associatesas of 2024-06-30 | 189,557 | $1.6M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 3.97% ($0.37/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-10 | $0.1333 | 2026-05-14 |
| 2025-08-15 | $0.0598 | 2025-09-18 |
| 2025-04-25 | $0.1246 | 2025-06-05 |
| 2024-08-16 | $0.0527 | 2024-09-19 |
| 2024-03-14 | $0.1053 | 2024-05-16 |
| 2023-08-24 | $0.0439 | 2023-10-05 |
Recent trades on TradeandTell
No one on the platform has traded HLN yet.
